Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 13, Issue 3, Pages 333-346Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161207779313551
Keywords
inflammation; remodeling; acute therapy; topical; cardiovascular disease
Categories
Ask authors/readers for more resources
The matrix metalloproteinase family of enzymes has been a pharmaceutical target for over 20 years. In that time, many drugs have been developed but none have successfully passed clinical trials. A significant problem has been development of dose-limiting side-effects that were revealed during long-term clinical trials in diseases such as arthritis and various cancers. There are, however, other clinical settings where evidence for MMP function contributing to the pathophysiology of disease is strong. A number of these settings will be discussed here together with evidence from animal models that MMP inhibition is a valid strategy to be considered. A major advantage with many of these settings is that drug exposure may not have to be long-term and/or systemic thus reducing the possibility that side-effects will stymie MMPI-based therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available